Replies to post #243799 on Biotech Values

[dewophile]

I'm not sure if this updated data from a more recent cut of the data, or just subgroup analysis from data that was already released
I don't think AZN or GSK are particularly worried at this point, although GSK is probably more vulnerable given they enjoy having the sole label in the non-HRD (HRP) population